Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Results View source PDF Explain this filing

MEDPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹825.00

prior close

₹804.20

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-3.5% vs market

Retailing peers, median of 49sector · industry level-0.4%-3.2% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.2 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

-0.3

15m

-0.1

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6-0.1-3.5-0.4-3.2

Next day

-0.1+4.5-4.6+2.2-2.3

+0.0+6.2-6.2+3.0-3.0

-0.6+7.9-8.6+3.3-3.9

-0.6+9.0-9.6+4.3-4.9

+7.4+9.9-2.5+5.7+1.7

+6.1+10.0-3.9+4.0+2.1

15d

+16.4+13.1+3.4+2.7+13.7

+8.6+15.5-6.9+3.3+5.3

+3.4+16.8-13.4+6.0-2.6

+0.6+11.3-10.7-0.3+0.9

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 49Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medplus Health Services has informed stock exchanges that it has received two Stay Orders against a previously reported suspension from authorities in Bhandara, Maharashtra. This is an update to its earlier submission dated 13 February 2025. The Stay Orders effectively pause or overturn the earlier suspension action against the company in that jurisdiction. The full details have been posted on the company's website and on the BSE/NSE portals.

Likely market impact

Positive short-term relief for shareholders as the regulatory action against the company in Bhandara has been stayed, reducing immediate operational risk in that region. However, the matter remains under adjudication, so the final outcome is still pending.